NervGen Pharma (TSXV:NGEN) Beginning Cash Position : C$26.56 Mil (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Beginning Cash Position?

NervGen Pharma's Beginning Cash Position for the quarter that ended in Sep. 2024 was C$26.56 Mil.

NervGen Pharma's quarterly Beginning Cash Position increased from Mar. 2024 (C$11.66 Mil) to Jun. 2024 (C$30.31 Mil) but then declined from Jun. 2024 (C$30.31 Mil) to Sep. 2024 (C$26.56 Mil).

NervGen Pharma's annual Beginning Cash Position increased from Dec. 2021 (C$5.60 Mil) to Dec. 2022 (C$16.93 Mil) and increased from Dec. 2022 (C$16.93 Mil) to Dec. 2023 (C$22.45 Mil).

NervGen Pharma Beginning Cash Position Historical Data

The historical data trend for NervGen Pharma's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Beginning Cash Position Chart

NervGen Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

2.47

4.11

5.60

16.93

22.45

NervGen Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beginning Cash Position	Get a 7-Day Free Trial															16.08	14.79	11.66	30.31	26.56

NervGen Pharma Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

NervGen Pharma Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

NGENF:USA 9UA:Germany

Address

112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4

Website

https://www.nervgen.com

NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.

Executives

John Ruffolo	Director
Krista Mckerracher	Director
William Joseph Radvak	Director
Harold Punnett	10% Security Holder, Director
Robert Pilz	Senior Officer

NervGen Pharma Headlines

No Headlines